Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Instruments Automate PCR Diagnostic Applications

By LabMedica International staff writers
Posted on 27 Jan 2014
Two new diagnostic instruments, which recently have been certified for marketing in Europe (CE marked), will bring an unprecedented level of automation and efficiency to laboratories that process large and very large numbers of specimens on a daily basis.

The Roche Molecular Diagnostics (Pleasanton, CA, USA) Cobas 6800/8800 system has automated PCR technology for virology, blood screening, HPV (human papillomavirus and CT/NG (Chlamydia trachomatis and Neisseria gonorrhea) testing. More...
The system comes in two models—large (6800) and very-large (8800) throughput capacity—and was developed to deliver increased automation and throughput, with minimal user intervention and improved quality control.

The instruments are equipped with an onboard refrigerator to allow for significantly longer reagent storage capacity and less loading and unloading of reagents. The instrument design provides greater ergonomics in terms of the user-instrument interface, reducing the number of required user interactions. Once the instrument is loaded, the system can run continuously for eight or four hours for the Cobas 6800 and Cobas 8800 system, respectively. This translates into a throughput of 300 and 1000 results in eight hours, respectively. Once the instrument begins processing samples, the first 96 results can be reported within three-and-a-quarter hours. Thereafter, the Cobas 6800 and 8800 instruments provide up to 96 results every 90 or 30 minutes, respectively.

This level of efficiency was obtained by completely automating the processing of primary and secondary tubes all the way through to the patient sample result for any combination of three different tests at the same time. This parallel sample to result process is accomplished using a universal sample preparation, PCR profile, and reagent setup process.

During the first six months of the systems' CE launch, several assays will be available for virology labs (HIV, HCV, HBV, and CMV) and for blood screening labs (combined HIV/HCV/HBV, WNV, and combined Parvovirus B19/HAV). In the near future, the system will support additional assays including HPV, CT/NG, and a utility channel for user-defined applications.

Related Links:
Roche Molecular Diagnostics



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.